Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis

Blood

Volumn 98, Issue 3, 2001, Pages 586-593

  Anderson, Jeanne E ^a,b,c,d,e,g   Tefferi, Ayalew ^a,b,c,d,e,f   Craig, Fiona ^a,b,c,d,e,f   Holmberg, Leona ^a,b,c,d,e,f   Chauncey, Thomas ^a,b,c,d,e,f   Appelbaum, Frederick R ^a,b,c,d,e,f   Guardiola, Philippe ^a,b,c,d,e,f   Callander, Natalie ^a,b,c,d,e,f   Freytes, Cesar ^a,b,c,d,e,f   Gazitt, Yair ^a,b,c,d,e,f   Razvillas, Betty ^a,b,c,d,e,f   Joachim Deeg, H ^a,b,c,d,e,f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mayo Clinic ^*

^c MAYO CLINIC   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f SAINT LOUIS HOSPITAL   (France)

^g Katmai Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AZATHIOPRINE; BUSULFAN; CHLORAMBUCIL; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYDROXYUREA; INTERFERON; MYELOABLATIVE AGENT; PAMIDRONIC ACID; PHENYTOIN; STEROID; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; ERYTHROID CELL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN DETERMINATION; HUMAN; LYMPHOCYTE COUNT; MUCOSA INFLAMMATION; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; PRIORITY JOURNAL; SEIZURE; SPLENOMEGALY; STEADY STATE; SURVIVAL TIME; THROMBOCYTE COUNT; TOXICITY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0035437162     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.586     Document Type: Article

References (25)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
2. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
3. Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol. 1994;86:253-258.
4. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88:9-16.
5. Rameshwar P, Denny TN, Stein D, Gascón P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. J Immunol. 1994;153:2819-2830.
6. Dalley A, Smith JM, Reilly JT, Mac Neil S. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol. 1996;93:856-862.
7. Manoharan A, Pitney WR. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol. 1984;33:453-459.
8. Löfvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol. 1990;44:33-38.
9. Hasselbalch H, Lisse I. A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. Eur J Haematol. 1991;46:285-289.
10. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and marrow transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per II Trapianto del Modollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831-2838.
11. Wang JC, Cheung CP, Ahmed F, Steier W, Tobin MS. Circulating granulocyte and macrophage progenitor cells in primary and secondary myelofibrosis. Br J Haematol. 1983;54:301-307.
12. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and othermyeloproliferative disorders. Br J Haematol. 1984;57:495-503.
13. Craig JIO, Anthony RS, Parker AC. Circulating progenitor cells in myelofibrosis: the effect of recombinant α2b interferon in vivo and in vitro. Br J Haematol. 1991;78:155-160.
14. Barosi G, Viarengo G, Rosti V, Piaggio G, Marchetti M, Frassoni F. Clinical relevance of the number of circulating CD34-positive cells in myelofibrosis with myeloid metaplasia [abstract]. Blood 2000;96:744a.
15. Hasselbalch H, Jensen BA. Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance. Eur J Haematol. 1990;44:172-178.
16. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
17. Silverstein MN. Postpolycythemia myeloid metaplasia. Arch Intern Med. 1974;134:113-115.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1959;53:457.
19. Bauermeister DE. Quantitation of bone marrow reticulin - a normal range. Am J Clin Pathol. 1971;56:24-31.
20. Yoon S-Y, Li C-Y, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;106:682-688.
21. Burkhardt R, Bartl R, Jager K, et al. Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings. J Clin Pathol. 1986;39:237-252.
22. Olavarria E, Kanfer E, Szydlo R, et al. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloied leukaemia: a single-centre experience. Br J Haematol. 2000;108:769-777.
23. Tefferi A, Mesa RA, Nagomey DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
24. Elliott MA, Chen MG, Silverstein MN, Tefferi A. splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103:505-511.
25. Andréasson B, Swolin B, Kutti J. Increase of CD34 positive cells in polycythaemia vera. Eur J Haematol. 1997;59:171-176.